Skip to main content

Belgium Denmark Finland France Germany Greece Norway Spain Sweden Switzerland The Netherlands United Kingdom & Ireland

Login

For Healthcare
Professionals

Our products

Our products

Aspaveli
Tryngolza

Aspaveli

Unmet need
Targeted MOA
Efficacy
Safety
Dosing and Administration

Tryngolza

Balance Efficacy & Safety
MOA & pharmacodynamics
Taking Tryngolza

Unmet need

Study summaries

Efficacy

Demographics
Change over 52 weeks
Proteinuria reduction vs placebo
Proteinuria shift
Potential treatment algorithm
Adolescents
Post transplant
IS Status
eGFR adolescents
eGFR transplant
eGFR IS status

Safety

Safety 52 weeks
Tolerability in adolescents
TEAES in post transplant
Tolerability in IS and non IS

Dosing and Administration

Vaccination guidelines

Our products

Aspaveli
Tryngolza

Unmet need
Targeted MOA
Efficacy
Safety
Dosing and Administration

Study summaries

Demographics
Change over 52 weeks
Proteinuria reduction vs placebo
Proteinuria shift
Potential treatment algorithm
Adolescents
Post transplant
IS Status
eGFR adolescents
eGFR transplant
eGFR IS status

Safety 52 weeks
Tolerability in adolescents
TEAES in post transplant
Tolerability in IS and non IS

Vaccination guidelines

Balance Efficacy & Safety
MOA & pharmacodynamics
Taking Tryngolza

Home
Our products

Global-banner-products

Our products

Aspaveli
Tryngolza

Which information about our products are you looking for today?

Discover our products

Haematology

Aspaveli - Global product landing

Specialty Care

Tryngolza - Global

The information on this website is intended for Healthcare Professionals (HCPs) only.

Privacy Policy Terms of use Cookie policy Cookies Settings

Sobi - Swedish Orphan Biovitrum AB (publ), SE-112 76 Stockholm, Sweden

E-mail: [email protected]